Vinblastine Sulfate

Generic Name

Vinblastine Sulfate

Other Names

• Vinblastine

Drug Class

• Mitotic Inhibitor

Chemical Formula

C46H58N4O9S2

Molecular Weight

909.16 g/mol

Mechanism of Action

• Inhibition of microtubule formation

Indications

• Treatment of various cancers including lymphoma, Hodgkin's disease, breast cancer, testicular cancer, lung cancer, and others

Common Dosage Forms

• Injection

Typical Dosage

• 2-3.7 mg/m2 once a week

Pediatric Dosage

• Safety and efficacy not established in pediatric patients

Geriatric Dosage

• Dosage adjustment may be required based on renal function

Side Effects

• Bone marrow suppression, gastrointestinal disturbances, peripheral neuropathy, hair loss, hypersensitivity reactions

Contraindications

• Hypersensitivity to vinblastine, severe hepatic impairment, pregnancy

Pregnancy Category

• D

Lactation Safety

• Not recommended during breastfeeding due to potential risks

Drug Interactions

• Strong CYP3A4 inhibitors may increase vinblastine levels

Overdose Symptoms

• Severe myelosuppression, neurotoxicity

Antidote for Overdose

• Supportive care and appropriate management of symptoms

Storage Conditions

• Store at 2-8°C, protect from light

Pharmacokinetics

• Absorption: Well absorbed after intravenous administration
• Distribution: Rapid distribution in tissues
• Metabolism: Metabolized in the liver
• Excretion: Primarily excreted in bile and feces

Precautions

• Monitor for myelosuppression, neuropathy, and allergic reactions during therapy

Warnings

• Administer under the supervision of a qualified healthcare provider experienced in chemotherapy

Others

• Regular blood tests are required to monitor for adverse effects and therapeutic response